Dr. Reddy's Laboratories Limited (FRA:RDDA)

Market Cap	9.96B -10.7%
Revenue (ttm)	3.28B +11.1%
Net Income	536.36M +5.4%
EPS	0.64 +5.6%
Shares Out	n/a
PE Ratio	18.57
Forward PE	22.47
Dividend	0.06 (0.51%)
Ex-Dividend Date	Jul 25, 2025

Volume	n/a
Average Volume	239
Open	12.00
Previous Close	12.40
Day's Range	12.00 - 12.00
52-Week Range	10.20 - 13.80
Beta	n/a
RSI	56.51
Earnings Date	May 8, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 27,811
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RDDA

Financial Performance

In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.

Financial numbers in INR